Vivesto AB (Vivesto AB) ROCE % : -116.92% (As of Dec. 2023)

View and export this data going back to 2015. Start your Free Trial

What is Vivesto AB ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Vivesto AB's annualized ROCE % for the quarter that ended in Dec. 2023 was -116.92%.

Vivesto AB ROCE % Historical Data

The historical data trend for Vivesto AB's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Vivesto AB ROCE % Chart

Vivesto AB Annual Data

Trend

Apr14

Apr15

Apr16

Apr17

Apr18

Apr19

Apr20

Dec21

Dec22

Dec23

ROCE %

Get a 7-Day Free Trial

-38.13

-5.09

-19.35

-74.31

-49.50

Vivesto AB Quarterly Data
	Jan19	Apr19	Jul19	Oct19	Jan20	Apr20	Jul20	Oct20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
ROCE %	Get a 7-Day Free Trial															-207.73	-25.37	-37.46	-22.66	-116.92

Vivesto AB ROCE % Calculation

Vivesto AB's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	-12.551	/	( ( (33.575 - 2.147)	+	(21.513 - 2.23) )	/ 2 )
	=	-12.551	/	( (31.428	+	19.283)	/ 2 )
	=	-12.551	/	25.3555
	=	-49.50 %

Vivesto AB's ROCE % of for the quarter that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Dec. 2023 )		(Q: Sep. 2023 )		(Q: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Dec. 2023 )		(Q: Sep. 2023 )		(Q: Dec. 2023 )
	=	-25.228	/	( ( (25.574 - 1.704)	+	(21.513 - 2.23) )	/ 2 )
	=	-25.228	/	( ( 23.87	+	19.283 )	/ 2 )
	=	-25.228	/	21.5765
	=	-116.92 %

(1) Note: The EBIT data used here is four times the quarterly (Dec. 2023) EBIT data.

Vivesto AB (OTCPK:OASMY) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Vivesto AB ROCE % Related Terms

Thank you for viewing the detailed overview of Vivesto AB's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Vivesto AB (Vivesto AB) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Vivesto AB (OTCPK:OASMY) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

VIVE:Sweden OMAX:Germany

Address

Gustav III:s Boulevard 46, 5th Floor, Solna, SWE, SE-169 73

Website

https://www.vivesto.com

Vivesto AB is a research and development company that develops new treatment options for patients suffering from difficult-to-treat cancer. The company's product development leverages its proprietary technology platforms to manufacture novel drug formulations that are intended to demonstrate improved properties in comparison with current alternatives, which can lead to a reduced side-effect profile and an expanded therapeutic area. The company has a portfolio of projects targeting cancer treatments.